Schott Pharma stock trades at EUR 24.65 near its 52-week high

Published on 09/25/2026 at 14:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JPMorgan started coverage on September 15, 2026, with an Overweight rating and a EUR 27.10 target. The June quarter produced EUR 281.76 million in revenue and EUR 0.26 EPS.

Pop-Art-Comic zeigt Techniker im Reinraum an Fertigspritzen-Karussell — SCHOTT Pharma (DE000A3ENQ51) inszeniert einen Pop-Art-Comic mit Techniker am Fertigspritzen-Karussell in einem sterilen Reinraum, Illustration mit AI erstellt.

Schott Pharma stock (ISIN DE000A3ENQ51) was trading at EUR 24.65 on Xetra on September 25, 2026, at 1:58 p.m. CEST, up 0.20 percent from the previous close. The price stood 0.40 percent below its 52-week high of EUR 24.75, keeping the chart close to its yearly peak.

Stock holds near yearly high

The intraday range extended from EUR 24.55 to EUR 24.75 on September 25, 2026, while market capitalization stood at EUR 3,712,650,284. The distance from the 52-week low of EUR 12.68 to the current quote underscores the stock's wide twelve-month range.

For investors, the immediate technical signal is the narrow gap to the yearly high rather than a large daily move. The 0.20 percent gain places the stock near the upper end of its current trading range, but does not by itself establish a new record.

Revenue grows while EPS declines

Finanzen reported that Schott Pharma published its quarter ended June 30, 2026, on August 12, 2026, with revenue of EUR 281.76 million and EPS of EUR 0.26.

The revenue figure was 9.87 percent above EUR 256.46 million in the prior-year quarter, according to Finanzen. EPS declined from EUR 0.30 to EUR 0.26, a decrease of 13.33 percent, creating a split between top-line growth and per-share earnings.

JPMorgan sets EUR 27.10 target

MarketScreener reported on September 15, 2026, that JPMorgan initiated coverage with an Overweight rating and a EUR 27.10 price target.

The target lies 9.94 percent above the EUR 24.65 intraday price. JPMorgan's published view therefore provides a concrete valuation reference, while the June-quarter EPS decline remains the main counterweight to the 9.87 percent revenue increase.

Schott Pharma stock stays elevated

Schott Pharma stock was trading at EUR 24.65 on Xetra on September 25, 2026, at 1:58 p.m. CEST. The quote was EUR 0.10 above the previous close and EUR 0.10 below the session high of EUR 24.75.